Motesanib diphosphate (AMG 706), an oral angiogenesis inhibitor, demonstrates clinical efficacy in advanced thymoma

Acta Oncol. 2009;48(4):619-21. doi: 10.1080/02841860802495362.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Oral
  • Adult
  • Angiogenesis Inhibitors / administration & dosage
  • Angiogenesis Inhibitors / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Chemotherapy, Adjuvant
  • Humans
  • Indoles / administration & dosage
  • Indoles / therapeutic use*
  • Male
  • Neoplasm, Residual / drug therapy
  • Niacinamide / administration & dosage
  • Niacinamide / analogs & derivatives*
  • Niacinamide / therapeutic use
  • Oligonucleotides
  • Pleural Neoplasms / drug therapy*
  • Pleural Neoplasms / secondary*
  • Radiotherapy, Adjuvant
  • Thymoma / drug therapy*
  • Thymoma / radiotherapy
  • Thymoma / secondary*
  • Thymoma / surgery
  • Thymus Neoplasms / pathology*
  • Thymus Neoplasms / radiotherapy
  • Thymus Neoplasms / surgery
  • Treatment Outcome

Substances

  • Angiogenesis Inhibitors
  • Indoles
  • Oligonucleotides
  • Niacinamide
  • imetelstat